Claris Life sciences is currently trading at Rs. 228.00, up by 3.45 points or 1.54% from its previous closing of Rs. 224.55 on the BSE.
The scrip opened at Rs. 226.60 and has touched a high and low of Rs. 228.85 and Rs. 224.00 respectively. So far 52876 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 98.10 on 19-Dec-2011.
Last one week high and low of the scrip stood at Rs. 266.90 and Rs. 216.00 respectively. The current market cap of the company is Rs. 1436.86 crore.
The promoters holding in the company stood at 62.06% while Institutions and Non-Institutions held 23.17% and 14.77% respectively.
Ahmedabad-based sterile injectables pharmaceutical firm, Claris Life sciences, is planning to invest Rs 900 crore, a part of divestment of 80 per cent stake in its infusion business, on various initiatives, including growth of business and pre-payment of debt.
Recently, the company divested 80 per cent stake in its infusion business for a total consideration of Rs 1,050 crore and has entered into a tripartite joint venture with two Japanese firms for the same. Drug firm executed agreements for a joint venture Claris-Otsuka; with Japan-based Otsuka Pharmaceutical Factory (OPF) and Mitsui & Co Ltd for its infusion business in India and emerging markets.
Further, besides earmarking Rs 900 crore for various initiatives, the company plans to utilize another Rs 300 crore for organic and inorganic growth of the speciality injectables business.
Ahmedabad based, Claris Lifesciences offers injectibles in various therapeutic segments including anesthesia, critical care, anti-infectives, renal care, infusion therapy, parenteral nutrition and oncology. It has presence in 91 countries across Latin America, Europe, Gulf, Africa, CIS, Central Asia and Asia- Pacific.
| Company Name | CMP |
|---|---|
| Redington | 228.00 |
| Adani Enterprises | 2229.15 |
| Amrapali Industries | 17.36 |
| Rashi Peripheral | 474.85 |
| PDS | 294.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: